What is the projected market valuation of the Swine Health Market by 2035?

The Swine Health Market is projected to reach approximately 7.795 USD Billion by 2035. Read More

What was the market valuation of the Swine Health Market in 2024?

In 2024, the Swine Health Market was valued at 5.01 USD Billion. Read More

What is the expected CAGR for the Swine Health Market during the forecast period 2025 - 2035?

The expected CAGR for the Swine Health Market during the forecast period 2025 - 2035 is 4.1%. Read More

Which product type segment is anticipated to show the highest growth in the Swine Health Market?

The Nutritional Additives segment is expected to grow from 1.41 USD Billion in 2024 to 2.295 USD Billion by 2035. Read More

Which administrative route is projected to dominate the Swine Health Market?

The Injectable route is projected to dominate, growing from 2.0 USD Billion in 2024 to 3.0 USD Billion by 2035. Read More

What is the expected growth of the Commercial Swine Farms segment by 2035?

The Commercial Swine Farms segment is expected to grow from 2.505 USD Billion in 2024 to 4.025 USD Billion by 2035. Read More

Who are the leading companies in the Swine Health Market?

Key players include Zoetis, Merck Animal Health, Boehringer Ingelheim, and Elanco Animal Health. Read More

What was the valuation of the Diagnostics segment in 2024?

The Diagnostics segment was valued at 0.9 USD Billion in 2024. Read More

How does the market for Porcine Reproductive and Respiratory Syndrome compare to other diseases?

The market for Porcine Reproductive and Respiratory Syndrome is projected to grow from 1.5 USD Billion in 2024 to 2.2 USD Billion by 2035, indicating substantial demand. Read More

Swine Health Market

Q: What are the key diseases affecting the Swine Health Market?

Key diseases include Porcine Respiratory Disease, Porcine Reproductive and Respiratory Syndrome, Porcine Parvovirus, and Swine Influenza. Read More

Swine Health Market Research Report: Size, Share, Trend Analysis By Product Type (Vaccines, Medicines, Diagnostics, Nutritional Additives), By Disease (Porcine Respiratory Disease, Porcine Reproductive and Respiratory Syndrome, Porcine Parvovirus, Swine Influenza), By Administrative Route (Oral, Injectable, Intra-nasal), By End Use (Commercial Swine Farms, Veterinary Clinics, Research Institutions) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

4.1%

2024 Market Size

$ 5.01 Billion

2035 Market Size

$ 7.8 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/41846-HCR | Pages: 200 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Product Type (USD Billion)
  1. 4.1.1 Vaccines
  2. 4.1.2 Medicines
  3. 4.1.3 Diagnostics
  4. 4.1.4 Nutritional Additives
2. 4.2 Healthcare, BY Disease (USD Billion)
  1. 4.2.1 Porcine Respiratory Disease
  2. 4.2.2 Porcine Reproductive and Respiratory Syndrome
  3. 4.2.3 Porcine Parvovirus
  4. 4.2.4 Swine Influenza
3. 4.3 Healthcare, BY Administrative Route (USD Billion)
  1. 4.3.1 Oral
  2. 4.3.2 Injectable
  3. 4.3.3 Intra-nasal
4. 4.4 Healthcare, BY End Use (USD Billion)
  1. 4.4.1 Commercial Swine Farms
  2. 4.4.2 Veterinary Clinics
  3. 4.4.3 Research Institutions
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Zoetis (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck Animal Health (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Boehringer Ingelheim (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Elanco Animal Health (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Ceva Santé Animale (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Virbac (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Huvepharma (BG)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Phibro Animal Health (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Alltech (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY PRODUCT TYPE
4. 6.4 US MARKET ANALYSIS BY DISEASE
5. 6.5 US MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
6. 6.6 US MARKET ANALYSIS BY END USE
7. 6.7 CANADA MARKET ANALYSIS BY PRODUCT TYPE
8. 6.8 CANADA MARKET ANALYSIS BY DISEASE
9. 6.9 CANADA MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
10. 6.10 CANADA MARKET ANALYSIS BY END USE
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY PRODUCT TYPE
13. 6.13 GERMANY MARKET ANALYSIS BY DISEASE
14. 6.14 GERMANY MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
15. 6.15 GERMANY MARKET ANALYSIS BY END USE
16. 6.16 UK MARKET ANALYSIS BY PRODUCT TYPE
17. 6.17 UK MARKET ANALYSIS BY DISEASE
18. 6.18 UK MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
19. 6.19 UK MARKET ANALYSIS BY END USE
20. 6.20 FRANCE MARKET ANALYSIS BY PRODUCT TYPE
21. 6.21 FRANCE MARKET ANALYSIS BY DISEASE
22. 6.22 FRANCE MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
23. 6.23 FRANCE MARKET ANALYSIS BY END USE
24. 6.24 RUSSIA MARKET ANALYSIS BY PRODUCT TYPE
25. 6.25 RUSSIA MARKET ANALYSIS BY DISEASE
26. 6.26 RUSSIA MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
27. 6.27 RUSSIA MARKET ANALYSIS BY END USE
28. 6.28 ITALY MARKET ANALYSIS BY PRODUCT TYPE
29. 6.29 ITALY MARKET ANALYSIS BY DISEASE
30. 6.30 ITALY MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
31. 6.31 ITALY MARKET ANALYSIS BY END USE
32. 6.32 SPAIN MARKET ANALYSIS BY PRODUCT TYPE
33. 6.33 SPAIN MARKET ANALYSIS BY DISEASE
34. 6.34 SPAIN MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
35. 6.35 SPAIN MARKET ANALYSIS BY END USE
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY PRODUCT TYPE
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY DISEASE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USE
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY PRODUCT TYPE
42. 6.42 CHINA MARKET ANALYSIS BY DISEASE
43. 6.43 CHINA MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
44. 6.44 CHINA MARKET ANALYSIS BY END USE
45. 6.45 INDIA MARKET ANALYSIS BY PRODUCT TYPE
46. 6.46 INDIA MARKET ANALYSIS BY DISEASE
47. 6.47 INDIA MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
48. 6.48 INDIA MARKET ANALYSIS BY END USE
49. 6.49 JAPAN MARKET ANALYSIS BY PRODUCT TYPE
50. 6.50 JAPAN MARKET ANALYSIS BY DISEASE
51. 6.51 JAPAN MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
52. 6.52 JAPAN MARKET ANALYSIS BY END USE
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY PRODUCT TYPE
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY DISEASE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USE
57. 6.57 MALAYSIA MARKET ANALYSIS BY PRODUCT TYPE
58. 6.58 MALAYSIA MARKET ANALYSIS BY DISEASE
59. 6.59 MALAYSIA MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
60. 6.60 MALAYSIA MARKET ANALYSIS BY END USE
61. 6.61 THAILAND MARKET ANALYSIS BY PRODUCT TYPE
62. 6.62 THAILAND MARKET ANALYSIS BY DISEASE
63. 6.63 THAILAND MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
64. 6.64 THAILAND MARKET ANALYSIS BY END USE
65. 6.65 INDONESIA MARKET ANALYSIS BY PRODUCT TYPE
66. 6.66 INDONESIA MARKET ANALYSIS BY DISEASE
67. 6.67 INDONESIA MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
68. 6.68 INDONESIA MARKET ANALYSIS BY END USE
69. 6.69 REST OF APAC MARKET ANALYSIS BY PRODUCT TYPE
70. 6.70 REST OF APAC MARKET ANALYSIS BY DISEASE
71. 6.71 REST OF APAC MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
72. 6.72 REST OF APAC MARKET ANALYSIS BY END USE
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY PRODUCT TYPE
75. 6.75 BRAZIL MARKET ANALYSIS BY DISEASE
76. 6.76 BRAZIL MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
77. 6.77 BRAZIL MARKET ANALYSIS BY END USE
78. 6.78 MEXICO MARKET ANALYSIS BY PRODUCT TYPE
79. 6.79 MEXICO MARKET ANALYSIS BY DISEASE
80. 6.80 MEXICO MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
81. 6.81 MEXICO MARKET ANALYSIS BY END USE
82. 6.82 ARGENTINA MARKET ANALYSIS BY PRODUCT TYPE
83. 6.83 ARGENTINA MARKET ANALYSIS BY DISEASE
84. 6.84 ARGENTINA MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
85. 6.85 ARGENTINA MARKET ANALYSIS BY END USE
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRODUCT TYPE
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY PRODUCT TYPE
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DISEASE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USE
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY PRODUCT TYPE
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DISEASE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USE
99. 6.99 REST OF MEA MARKET ANALYSIS BY PRODUCT TYPE
100. 6.100 REST OF MEA MARKET ANALYSIS BY DISEASE
101. 6.101 REST OF MEA MARKET ANALYSIS BY ADMINISTRATIVE ROUTE
102. 6.102 REST OF MEA MARKET ANALYSIS BY END USE
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY PRODUCT TYPE, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY PRODUCT TYPE, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY DISEASE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY DISEASE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY ADMINISTRATIVE ROUTE, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY ADMINISTRATIVE ROUTE, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY END USE, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.2.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.2.4 BY END USE, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.3.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.3.4 BY END USE, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.4.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.4.4 BY END USE, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.5.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.5.4 BY END USE, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.6.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.6.4 BY END USE, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.7.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.7.4 BY END USE, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.8.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.8.4 BY END USE, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.9.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.9.4 BY END USE, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.10.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.10.4 BY END USE, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.11.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.11.4 BY END USE, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.12.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.12.4 BY END USE, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.13.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.13.4 BY END USE, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.14.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.14.4 BY END USE, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.15.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.15.4 BY END USE, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.16.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.16.4 BY END USE, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.17.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.17.4 BY END USE, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.18.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.18.4 BY END USE, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.19.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.19.4 BY END USE, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.20.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.20.4 BY END USE, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.21.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.21.4 BY END USE, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.22.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.22.4 BY END USE, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.23.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.23.4 BY END USE, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.24.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.24.4 BY END USE, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.25.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.25.4 BY END USE, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.26.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.26.4 BY END USE, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.27.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.27.4 BY END USE, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.28.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.28.4 BY END USE, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.29.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.29.4 BY END USE, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY DISEASE, 2025-2035 (USD Billion)
  3. 7.30.3 BY ADMINISTRATIVE ROUTE, 2025-2035 (USD Billion)
  4. 7.30.4 BY END USE, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Swine Health Market Segmentation

Swine Health Market By Product Type (USD Billion, 2025-2035)

Vaccines
Medicines
Diagnostics
Nutritional Additives

Swine Health Market By Disease (USD Billion, 2025-2035)

Porcine Respiratory Disease
Porcine Reproductive and Respiratory Syndrome
Porcine Parvovirus
Swine Influenza

Swine Health Market By Administrative Route (USD Billion, 2025-2035)

Oral
Injectable
Intra-nasal

Swine Health Market By End Use (USD Billion, 2025-2035)

Commercial Swine Farms
Veterinary Clinics
Research Institutions

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”